Warwick Medical School, University of Warwick, Warwick, Coventry, UK
Warwick Medical School, University of Warwick, Warwick, Coventry, UK.
BMJ Open. 2022 Jul 15;12(7):e052487. doi: 10.1136/bmjopen-2021-052487.
Cardiovascular disease (CVD) is the leading cause of death worldwide, with significantly worse CVD outcomes in ethnic minorities in developed countries, especially South Asians, compared with the prevailing white ethnic group. This protocol outlines the process for conducting a systematic literature review to investigate the CVD outcome inequalities between South Asian and white Caucasian ethnic groups.
Studies that compared the South Asian ethnic minority with the predominant white ethnicity in developed countries with CVD will be included from inception to 22 April 2021. We will search MEDLINE, Embase, Web of Science and grey literature to find all relevant peer-reviewed articles, reports and online theses. Articles will be screened using inclusion/exclusion criteria applied first at the title and abstract level, and then full texts, both by two independent reviewers. Articles kept in the review will undergo a risk of bias assessment using the Quality In Prognosis Studies tool and data will be extracted. Random-effects meta-analysis and heterogeneity tests will be undertaken, and tests for publication bias, outlying highly-influential observations. If insufficient data is founded or studies are highly heterogeneous, a narrative synthesis will be conducted.
Formal ethical approval is not required for this review.
The results and findings of this systematic literature review will be disseminated through peer-reviewed publications and reports.
CRD42021240865.
心血管疾病(CVD)是全球范围内的主要死因,在发达国家,少数民族的 CVD 结局明显比白人族群更差,尤其是南亚裔。本方案概述了开展系统文献综述的过程,以调查南亚裔和白种高加索族群之间 CVD 结局不平等的情况。
从最初到 2021 年 4 月 22 日,我们将纳入比较 CVD 中少数民族南亚裔与发达国家主要白种族群的研究。我们将搜索 MEDLINE、Embase、Web of Science 和灰色文献,以找到所有相关的同行评议文章、报告和在线论文。文章将通过先在标题和摘要层面,然后在全文层面,由两名独立评审员应用纳入/排除标准进行筛选。保留在综述中的文章将使用预后研究质量工具进行偏倚风险评估,并提取数据。如果数据不足或研究高度异质,将进行叙述性综合分析。
本综述不需要正式的伦理批准。
本系统文献综述的结果和发现将通过同行评议的出版物和报告进行传播。
PROSPERO 注册号:CRD42021240865。